Form 4: MIMEDX Director William Hawkins Receives Annual Restricted Stock Grant

MIMEDX Group, Inc. Director William A. Hawkins reported the acquisition of 28,609 shares of common stock as part of an annual restricted stock grant, increasing his total beneficial ownership to 204,018 shares.

Summary

• William A. Hawkins, a Director of MIMEDX GROUP, INC. (MDXG), acquired 28,609 shares of common stock.
• The transaction occurred on June 18, 2025, at a price of $6.47 per share.
• This acquisition represents an annual restricted stock grant to non-employee directors.
• The grant is exempt under SEC Rule 16b-3.
• Following this transaction, Mr. Hawkins beneficially owns a total of 204,018 shares of MIMEDX common stock.
• The award vests upon the earlier of 12 months or the next annual meeting of shareholders.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The document reports a routine, expected insider transaction (restricted stock grant) which is generally viewed positively as it aligns director interests with shareholders. There are no negative or unexpected elements.

Positives

• The grant of restricted stock to a director aligns the director's interests with those of shareholders, as their compensation is tied to the company's stock performance.
• The transaction is part of a pre-arranged plan (Rule 10b5-1(c)), indicating a structured approach to insider compensation and stock acquisition.

Future Outlook

The restricted stock award vests upon the earlier of 12 months from the grant date or the next annual meeting of shareholders, indicating a future milestone for the shares to become fully owned.

Industry Context

This Form 4 filing reflects a routine compensation event for a non-employee director, common across publicly traded companies in various industries, including the healthcare and medical device sector where MIMEDX operates. It does not provide specific insights into broader industry trends beyond standard corporate governance practices.

Comparison to Industry Standards

• The practice of granting restricted stock to non-employee directors is a standard compensation mechanism across industries, including healthcare, aligning director incentives with long-term shareholder value.
• The use of Rule 10b5-1 plans for such grants is also a common corporate governance practice, providing a legal framework for insiders to acquire or dispose of securities in a pre-planned manner, reducing concerns about insider trading.

Corporate Governance

Related Party Transactions

• The acquisition of 28,609 shares by Director William A. Hawkins is a related party transaction, specifically an annual restricted stock grant from the company to a non-employee director.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's stock performance, potentially encouraging decisions that benefit long-term shareholder value.
• Employees: No direct impact mentioned, but general corporate governance practices can indirectly affect employee morale and stability.
• Management: The transaction is part of the compensation structure for non-employee directors, reflecting standard governance practices.

Next Steps

• The restricted stock award will vest upon the earlier of 12 months from the grant date (June 18, 2025) or the next annual meeting of shareholders.

Key Dates

Keywords

MIMEDX GROUP, MDXG, SEC Form 4, Insider Transaction, Restricted Stock Grant, Director Compensation, Equity Acquisition, Stock Ownership, Rule 10b5-1, Corporate Governance